Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 346-354

  Hochhauser, Daniel ^a   Kotecha, Minal ^a   O'Hare, Caroline ^b   Morris, Peter J ^b   Hartley, Janet M ^b   Taherbhai, Zarmeen ^c   Harris, Dorothy ^c   Forni, Claudia ^d   Mantovani, Roberto ^d   Lee, Moses ^c,e   Hartley, John A ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c FURMAN UNIVERSITY   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e HOPE COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT BINDING FACTOR; DEOXYRIBONUCLEASE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; JH 37; MESSENGER RNA; NUCLEAR FACTOR Y; POLYAMIDE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; NYLON; TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

ARTICLE; BINDING SITE; CELL STRAIN 3T3; CELL VIABILITY; CHROMATIN; COMET ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA FLANKING REGION; DNA FOOTPRINTING; DNA SEQUENCE; DNA STRAND BREAKAGE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING;

ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CHROMATIN IMMUNOPRECIPITATION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; GENE EXPRESSION; MICE; NIH 3T3 CELLS; NYLONS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 33846847632     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0503     Document Type: Article

References (37)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
2. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998;1400:121-37.
3. Furukawa M, Uchiumi T, Nomoto M, et al. The role of an inverted CCAAT element in transcriptional activation of the human DNA top-oisomerase IIα gene by heat shock. J Biol Chem 1998;273:10550-5.
4. Sandri MI, Isaacs RJ, Ongkeko WM, et al. p53 regulates the minimal promoter of the human topoisomerase IIα gene. Nucleic Acids Res 1996; 24:4464-70.
5. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent top-oisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987;47: 3973-9.
6. Burden DA, Osheroff N. Mechanism of action of eukaryotic top-oisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139-54.
7. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1998;263:17724-9.
8. Fry AM, Chresta CM, Davies SM, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-5.
9. Kubo T, Kohno K, Ohga T, et al. DNA topoisomerase IIα gene expression under transcriptional control in etoposide /teniposide-resistant human cancer cells. Cancer Res 1995;55:3860-4.
10. Dimanche-Boitrel MT, Pelletier H, Genne P, et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 1992;50:677-82.
11. Desoize B, Jardillier JC. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000;36:193-207.
12. Hochhauser D, Stanway CA, Harris AL, Hickson ID. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J Biol Chem 1992;267:18961-5.
13. Isaacs RJ, Harris AL, Hickson ID. Regulation of the human top-oisomerase IIα gene promoter in confluence-arrested cells. J Biol Chem 1996;271:16741-7.
14. Adachi N, Kobayashi M, Koyama H. Cell cycle-dependent regulation of the mouse DNA topoisomerase IIα. gene promoter. Biochem Biophys Res Commun 1997;230:105-9.
15. Marchini S, Broggini M, Sessa C, D'Incalci M. Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs 2001;10:1703-14.
16. Tolner B, Hartley JA, Hochhauser D. Transcriptional regulation of topoisomerase IIα at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol Pharmacol 2001;59: 699-706.
17. Melander C, Burnett R, Gottesfeld JM. Regulation of gene expression with pyrrole-imidazole polyamides. J Biotechnol 2004;112:195-220.
18. Henry JA, Le NM, Nguyen B, et al. Targeting the inverted CCAAT box 2 in the topoisomerase IIα promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies. Biochemistry 2004;43:12249-57.
19. Carey M, Smale ST. Electrophoretic mobility shift assays in transcriptional regulation in eukaryotes: concepts, strategies, and techniques, vol. 13. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2000. p. 493-6.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
21. Caretti G, Salsi V, Vecchi C, Imbriano C, Mantovani R. Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J Biol Chem 2003;278:30435-40.
22. Spanswick VJ, Hartley JIM, Ward TH, Hartley JA. Measurement of drug-induced interstrand crosslinking using single-cell gel electrophoresis (comet) assay. In: Brown R, Boger-Brown U, editors. Methods in molecular medicine, vol. 28: cytotoxic drug resistance mechanisms. Totowa (NJ): Humana Press; 1999.
23. Best TP, Edelson BS, Nickols NG, Dervan PB. Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Aced Sci U S A 2003;100:12063-8.
24. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999;239:15-27.
25. Falck J, Jensen PB, Sehested M. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIα gene. J Biol Chem 1999;274:18753-8.
26. Adachi N, Nomoto M, Kohno K, Koyama H. Cell-cycle regulation of the DNA topoisomerase promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene 2000;245:49-57.
27. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol Cell Biol 1997;17: 389-97.
28. Yun J, Chae HD, Choy HE, et al. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999;274:29677-82.
29. Soderlind KJ, Gorodetsky B, Singh AK, Bachur NR, Miller GG, Lown JW. Bis-benzimidazole anticancer agents: targeting human tumor helicases. Anti-Cancer Drug Des 1999;14:19-36.
30. Chen AY, Yu C, Bodley A, Pang LF, Liu LF. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 1993;53:1332-7.
31. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H. HMN-176 an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res 2003;63:6942-7.
32. Swalley SE, Baird EE, Dervan PB. Recognition ofa 5′-(A,T)GGG(A,T)2-3′ sequence in the minor groove of DNA by an eight-ring hairpin polyamide. J Am Chem Soc 1996;118:8198-206.
33. Dervan PB, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol 2003;13:284-99.
34. Dickinson LA, Burnett R, Melander C, et al. Arresting cancer proliferation by small-molecule gene regulation. Chem Biol 2004;11: 1583-94.
35. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000;64:221-53.
36. Lai YM, Fukuda N, Ueno T, et al. Synthetic pyrrole-imidazole polyamide inhibits expression of the human transforming growth factor-β11 gene. J Pharmacol Exp Ther 2005;315:571-5.
37. Matsuda H, Fukuda N, Ueno T, et al. Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-β1 promoter for treatment of progressive renal diseases. J Am Soc Nephrol 2006;17: 422-32.